A leader in
mRNA Cell Therapy

With multiple assets in clinical and preclinical development (see Pipeline), Cartesian is a leader in mRNA Cell Therapy. Our mission is to unleash the reach and potential of cell therapy through mRNA engineering.

mRNA Cell Therapy is a new class of therapy that is designed to blend some of the best features from conventional nanoparticle-based mRNA therapy with conventional DNA-engineered cell therapy.

In contrast to conventional nanoparticle-based RNA therapies, mRNA Cell Therapy may have minimal immunogenicity with repeat dosing. It can also be engineered with tissue-specific homing proteins.

Compared to conventional, costly DNA-based cell therapies, mRNA Cell Therapy is designed to not require preconditioning chemotherapy, have predictable and controllable pharmacokinetics, and avoid the risk of genomic integration. mRNA Cell Therapy is potentially safer, more potent, and less expensive versus DNA analogs, and has the potential to be administered in the outpatient setting. In addition, mRNA Cell Therapy is designed to enable true combination therapy without vector cargo limits.

cGMP FACILITY

Cartesian operates a wholly-owned, state-of-the-art GMP manufacturing facility in Gaithersburg, Maryland. By conducting all manufacturing in-house, we are able to optimize our processes rapidly and iteratively while directly assuring adherence to our strict quality standards. The resulting products are potent yet safer, cost-effective investigational cell therapies that can be administered with minimal training and post-infusion monitoring.

Technology

Cartesian’s proprietary technology and manufacturing platform, RNA Armory®, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Compared to conventional DNA-based CAR T-cell therapies, our mRNA CAR-T cell program is designed to not require preconditioning chemotherapy, to have predictable and controllable pharmacokinetics, and to avoid the risk of genomic integration. Our off-the-shelf MSC programs leverage these cells’ clinical safety record and excellent capacity for protein secretion to deliver synergistic combinations of therapies directly to the site of disease.

Scroll to Top